Novedades

• FDA approves generic teriparatide and levetiracetam
• US generics launch and approval for Dr Reddy’s and Lupin
• Five Chinese companies join UN’s MPP for Covid-19 medicines
• South Korean companies to make generic Bridion and COVID-19 drugs

Investigación

• Japan’s drug shortage crisis: challenges and policy solutions
• Saudi FDA drug approvals and GMP inspections: trend analysis
• Generic medications in the Lebanese community: understanding and public perception
• Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study

General

• Crecimiento de medicamentos genéricos en Brasil y Venezuela
• EMA launches European shortages monitoring platform to tackle persistent medicine shortages
• Penetración de los medicamentos genéricos en México y Brasil
• FDA releases one-year progress report for the Generic Drug Cluster

Novedades

• EMA recommends approval for biosimilar omalizumab Adcomfo and pertuzumab Pebrilzo
• Canada approves multiple denosumab and ustekinumab biosimilars as global competition grows
• FDA approves Zimrixby (rituximab) and Garzulys (insulin aspart) biosimilars
• EMA recommends approval for biosimilar pegfilgrastim Cavoley

Investigación

• El HHS equipara biosimilares a genéricos y desata rechazo
• Biosimilar interchangeability: a necessary fix, but not a silver bullet
• EULAR 2025 RA guidelines streamlined as biosimilar expansion reshapes treatment sequencing
• Adopción de biosimilares en Chile: ¿Por qué se demora?

General

• FDA publishes draft strategy on interchangeable biosimilars following 2025 public workshop
• Medicines for Europe calls for Biotech Act reforms to address ‘biosimilar void’
• Biosimilars approved in Europe
• La SBR publica un posicionamiento sobre la intercambiabilidad segura entre biológicos originales y biosimilares

• Latin American Forum
• Fármacos complejos no biológicos
• Enfoque por país

• Directrices
• Políticas y legislación
• Informes

• Congresos
• Artículos patrocinados
• Enlaces patrocinados